Skip to main content
. 2017 Jan 11;2017(1):CD004759. doi: 10.1002/14651858.CD004759.pub2

NCT01046955.

Methods Randomised, open‐label, parallel assignment (phase 4)
Participants 38 participants, age > 14 years, 1st LD kidney transplant recipients
Interventions ATG versus alemtuzumab versus daclizumab
Outcomes Primary: effectiveness and toxicity at 3 years, patient and graft survival at 1 and 3 years
Secondary: incidence of adverse reactions at 1 and 3 years
Notes This study has been completed but no study results have been posted on Clinicaltrials.gov